Stelios Papadopoulos Regulus Therapeutics Inc. (RGLS) insider trading activity

Stelios Papadopoulos is of Regulus Therapeutics Inc.. Currently has a direct ownership of 1.04 Million shares of RGLS, which is worth approximately $8.57 Million. The most recent transaction as insider was on Apr 30, 2025, when has been sold 62,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.04M

6.39% 3M change

6.39% 12M change

Total Value Held $8.57 Million

STELIOS PAPADOPOULOS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 30 2025	BUY Grant, award, or other acquisition	-	62,500 Added 5.66%	1,040,888 Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	$400,000 $1.6 p/Share	250,000 Added 20.35%	978,388 Common Stock
Apr 13 2023	BUY Grant, award, or other acquisition	$199,978 $0.9 p/Share	222,198 Added 23.37%	728,388 Common Stock
Nov 30 2021	BUY Grant, award, or other acquisition	$800,000 $0.36 p/Share	2,222,222 Added 30.51%	5,061,929 Common Stock
Dec 04 2020	BUY Grant, award, or other acquisition	$499,923 $0.63 p/Share	793,528 Added 28.54%	1,986,729 Common Stock

Also insider at

EUCRW

Eucrates Biomedical Acquisition Corp.

Director

EXEL

EXELIXIS, INC. Healthcare

Director

BIIB

BIOGEN INC. Healthcare

Director

OVID

Ovid Therapeutics Inc. Healthcare